Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ethinyloestradiol and levonorgestrel, CP-690, 550+ ethinyloestradiol and levonorgestrel · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment Sequence 1 | EXPERIMENTAL | - |
| Treatment Sequence 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ethinyloestradiol (EE) and levonorgestrel (LN), CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN) | DRUG | Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID |
| CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN), ethinyloestradiol (EE) and levonorgestrel (LN) | DRUG | Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone |
Inclusion Criteria: * Healthy female subjects * No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis Exclusion Criteria: * Any medical reason which would contraindicate the administration of oral contraceptives * Clinically significant infections withi...